The UK and US have agreed to a key bilateral deal that will ensure zero tariffs on UK pharmaceutical shipments entering the US market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has agreed to raise expenditure on medicines through the NHS. This pledge guarantees that import taxes on these key exports will be held at nothing for a timeframe of the next three years.
This development is in response to recent warnings to hike tariffs on branded drug products, with potential rates mentioned as high as 100%.
"This agreement between the Britain bolsters the global environment for new treatments and introduces long-overdue equity to American-British medicine commerce," a statement noted.
Trade Importance
Medicines constitute one of the Britain's largest export categories to the US, which is clearly the largest market for leading British pharmaceutical firms.
Statistics indicate that in the year to the end of the third quarter, the UK exported pharmaceutical products worth over eleven billion pounds to the US. This figure accounted for a significant portion of all goods exports in that period.
"This guarantee safeguards employment, increases capital expenditure and paves the way for the UK to establish itself as a global hub for biotech and pharma," the Business and Trade Secretary commented.
Specific UK Commitments
The agreement includes several key pledges from the British government:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it considers new treatments to be too expensive by 25%.
- Boosted Medicine Funding: There is a goal to raise total public funding on drugs from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Payback Limit: The amount drug companies must refund to the NHS to control costs will be limited at fifteen percent. In the past, rebates were more than 20%.
Broader Context
The pact comes amid a long-running dispute between the drug companies and the UK government over drug pricing and regulatory access.
The disagreement were heightened by assertions that American patients were charged several times more for the equivalent treatments than people in the other developed nations.
Recently, several major drug company projects in the UK have been delayed or scrapped, while major investments have been pledged toward projects in the United States.
One official acknowledged that the NHS needed to invest a greater share on drugs, noting that its budget allocation on drugs had decreased as a percentage of its overall budget over the previous ten-year period.
